MktsMarkets

Keros Therapeutics, Inc.
NASDAQ: KROSKey statistics
KROS News
Stories mentioning KROS from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 367.00 | 385.00 | 14,262 | 18,168 | 211,246 | 3,042 | 388.00 | 37.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 16,097 | 17,912 | 19,519 | 43,503 | 48,709 | 45,631 | 49,225 | 40,515 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 26,244 | 29,655 | 29,646 | 57,985 | 59,206 | 56,296 | 59,045 | 50,476 |
| Operating Income (Loss) | (25,877) | (29,270) | (15,384) | (39,817) | 152,040 | (53,254) | (58,657) | (50,439) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (166.00) | 273.00 | (253.00) | (221.00) | (338.00) | (229.00) | (92.00) | (196.00) |
| Pretax Income | (23,708) | (24,975) | (8,704) | (32,918) | 158,494 | (45,726) | (52,956) | (45,257) |
| Tax Provision | 0.00 | (1,514) | (1,424) | (2,222) | 10,043 | 300.00 | 0.00 | 0.00 |
| Net Income (Loss) | (23,708) | (23,461) | (7,280) | (30,696) | 148,451 | (46,026) | (52,956) | (45,257) |
| Earnings Per Share (Basic) | (1.21) | (0.63) | (0.18) | (0.76) | 3.66 | (1.23) | (1.41) | (1.25) |
| Earnings Per Share (Diluted) | (1.21) | (0.62) | (0.18) | (0.76) | 3.62 | (1.23) | (1.41) | (1.25) |
| Weighted Average Shares Outstanding (Basic) | 19,630 | 37,221 | 40,623 | 40,613 | 40,559 | 37,438 | 37,591 | 36,103 |
| Weighted Average Shares Outstanding (Diluted) | 19,630 | 37,859 | 40,623 | 40,613 | 41,021 | 37,438 | 37,591 | 36,103 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About KROS
Keros Therapeutics, Inc. (NASDAQ: KROS) is a stock listed on the Nasdaq Stock Market under the ticker symbol KROS. It last traded at $9.17 (Nov 9, 2026, 4:00 PM ET), down 2.0% on the day. That gives Keros Therapeutics a market capitalisation of $185.8M.
Over the past 52 weeks KROS has traded between $9.26 and $22.55.
Revenue for the quarter ended Mar 31, 2026 was $367.0K; a net loss of $23.7M. Revenue was down 99.8% from $211.2M in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $367.0K | -$23.7M | -6459.9% |
| Dec 31, 2025 | $385.0K | -$23.5M | -6093.8% |
| Sep 30, 2025 | $14.3M | -$7.3M | -51.0% |
| Jun 30, 2025 | $18.2M | -$30.7M | -169.0% |
From Keros Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…